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THE EFFECT OF SELECTED ADJUVANTS ON THE IN VITRO 
PERCUTANEOUS PENETRATION OF BENZOCAINE 
Abstract of Dissertation 
This research project was designed to test whether the 
in vitro percutaneous penetration of benzocaine through 
human cadaver skin could be enhanced by dimethyl sulfoxide 
(DMSO), urea, polyoxyethylene (20) isohexadecyl ether and 
1-dodecylazacycloheptan-2-one (Azone) in propylene glycol/ 
:~------~w-a-rer-~.t-s-'E€-m-s. Se-l-1.l-:S.i-l-i-t-y-a-nGl-pG.r:-t-i-t4.on-in_g_o£~hen2D_c_ai_n__e__l,"'--'. n~----­
propylene glycol/water systems was investigated. The 
adjuvant effects were studied in a 60/40 (V/V) propylene 
glycol/water co-solvent system. 
The well known drug penetration enhancer dimethyl 
sulfoxide did not enhance the penetration of benzocaine at 
any concentration level of DMSO under the conditions of the 
experiment. This lack of enhancement effect was probably due 
to increased solubility of benzocaine in the DMSO/water system 
and a consequent decrease in the partitioning of drug into 
the skin. Urea enhanced benzocaine penetration initially but 
no significant steady-state penetration enhancement was 
noted. Polyoxyethylene (20) isohexadecyl ether appeared to 
retard rather than enhance the percutaneous penetration of 
benzocaine at concentrations below and around the critical 
micelle concentration. Azone showed concentration 
dependence for its enhancement effect on penetration of 
benzocaine. With 1% V/V Azone, the initial benzocaine 
penetration rate was higher compared to the other Azone 
concentrations. On the basis of comparative analysis of the 
steady-state rates, 5% V/V Azone was observed to be the 
most effective penetration enhancer for benzocaine. Azone 
also showed additive enhancement properties with increasing 
percentages of propylene glycol. 
The results of this investigation emphasize the 
importance of in vitro skin penetration studies prior to 
clinical evaluation. The results also underscore the 
importance of a proper experimental design that will 
minimize variables during the study in order to properly 
identify cause and effect relationships. 
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The study of medicaments applied topically has gained 
renewed interest in recent years. The skin is one of the 
largest organs in the body and the most readily accessible 
for application of drugs. However of all the tissues in the 
body, the skin surface is one of the least permeable. This 
impermeability is related to two factors: the absence of 
highly efficient specialized transport systems and the 
unique structure of the cells of the stratum corneum (1). 
In humans, the skin serves as a protective barrier against 
penetration of a variety of substances. The challenge of 
overcoming this barrier to promote effective drug delivery 
for local and systemic effects has been the subject of 
considerable research in both the pharmaceutical and 
dermatological fields (2). 
Local anesthetics are widely used in a variety of OTC 
products intended for relief of itch and pain --
particularly when associated with thermal burns and 
sunburn. Since both itch and pain are subserved by the same 
network of cutaneous nerves, increasing the intensity of a 
stimulus converts the itching sensation to one of pricking 
or burning. Increasing the intensity still more induces 
true pain (3). One of the most widely used local 
anesthetics in OTC burn and sunburn products is benzocaine 
2 
(ethyl aminobenzoate). It is used at concentrations ranging 
from 5 to 20% in a variety of dosage forms such as sprays, 
ointments, lotions, creams and foams (3). 
Many studies have been done on the action of local 
anesthetics on intact, abraded and burned skin, and on 
subcutaneous tissue. However in many of these studies, the 
assessment of anesthetics efficacy has been based largely 
upon subjective clinical impressions (4,5). It has been 
reported by Campbell and Adriani (6), that local 
anesthetics in general are not absorbed from the intact 
skin, but pass into the blood only if the skin is abraded 
or burned. This lack of efficacy of many OTC products in 
the relief of pain and itch has also been corrorborated by 
other in vivo studies of local anesthetics on intact and 
sunburned skin (3). There is a noticeable difference in 
absorption when local anesthetics are topically applied to 
skin and to mucous membrane. Most explanation have stressed 
the histological differences of these two types of 
epithelial coverings; but Adriani and Dalili (7) credit 
Herman Rein with demonstrating the presence of an 
electrostatic barrier effect in the skin, showing that 
isolated human skin behaved physiologically as a negatively 
charged membrane of single cell thickness. He postulated 
that electrostatic charges opposed the penetration of both 
anions and cations. It is possible that salts of local 
anesthetic agents do not penetrate this layer because they 
3 
are ionized. 
The stratum corneum is being constantly regenerated 
and has a turnover period of about two weeks. The process 
of regeneration begins with a high level of mitotic 
activity in the basal layer of the epidermis followed by 
the complex process of maturation and migration towards the 
and undergo intracellular transformation. The end result is 
the dense, keratin-filled and metabolically inactiy~ layer 
-------- ~···--~-·>·~---~··---~·••"••-"r'~·~·---0..-.----- • 
of cells. The three-dimensional protein matrix which fills 
the intracellular space contains at least two 
distinguishable forms of keratin: alpha-keratin, which is 
formed or woven into highly ordered filaments and 
constitutes about 70% of the intracellular content, and 
beta-keratin, which is amorphous or "noncrystalline" and 
approximates 10% of the total content. The residual 20% of 
the intracellular content is lipid, including cholesterol, 
fatty acids, and triglycerides. The intracellular contents 
are about 85% of the total stratum corneum on a dry weight 
basis. In its normal state the stratum corneum contains 
about 15% water (1). The stratum corneum or the "cornified" 
layer is a thin, ultradense polyphasic epidermal covering 
made from dehydrated, highly filamented dead cells which 
are fused into tight columnar arrangement held together 
primarily by tonofibrils and a somewhat indistinguishable 
substance. It has been estimated that stratum corneum 
4 
contains ten times the fibrous material in one-tenth the 
space as that of the viable epidermis. This forms the 
effective barrier of the skin. This composition of stratum 
corneum serves to explain the more recent view that the 
skin is composed of a complex number of barriers of varying 
degrees of penetrability. 
Each penetrant may encounter a different type of 
barrier, and the degree of penetration is subject to the 
chemical and physical properties and the interaction of the 
drug with the tissues it attempts to traverse (7). The 
stratum corneum, acts a passive diffusion medium, but one 
which displays considerable diffusional resistance. Since 
the mechanism of penetration through the stratum corneum is 
a diffusive process, Fick's law is generally applied to 
describe the process of skin penetration. In general the 
viable epidermis and dermis are relatively permeable to 
most substances. The stratum corneum is interspersed with 
hair follicles and its associated pilosebaceous glands (the 
eccrine and apocrine glands). The surface openings of these 
structures may provide an effective pathway for penetration 
of benzocaine, but their relative importance is doubtful 
since hair follicles and pilosebaceous glands occupy 
respectively only 1/1,000 and 1/10,000 of the total surface 
of skin. 
The skin also possesses an adsorptive capacity which 
offers a degree of protection against penetration by 
5 
retarding inward migration rather than augmenting 
penetration. This type of effect has not been documented 
with respect to benzocaine. 
The stratum corneum effectively acts as a 'barrier' to 
the percutaneous penetration of benzocaine and thus 
accounts for the reported lack of efficacy of many OTC 
products. Relatively poor penetrability of benzocaine 
accounts for the use of excessive high concentrations of 
the drug in commercial products. The only product rated as 
'effective' contains 20% of benzocaine and yet exhibits a 
relatively slow onset of action (3). Enhancement of rate of 
penetration of benzocaine topically could lower the 
concentration requirement for efficacy while providing a 
more immediate relief of pain. Incorporation of suitable 
adjuvants in the formulation could help to achieve this 
goal. 
Many substances when applied to the skin can alter the 
permeability properties of the stratum corneum. Of major 
interest are those substances that have a mild or 
reversible effect on the skin tissue. 
Polar solvents, such as dimethylsulfoxide (DMSO) and 
dimethylformamide (DMFA), have been shown by many 
investigators to be effective vehicles for increasing skin 
penetration (9-13). Brechner et ~· (10) reported that 
tetracaine base dissolved in DMSO penetrated the skin 
readily to produce local anesthesia. In vivo anesthesia was 
6 
obtained with concentration of tetracaine from 5 to 30%. 
However, Kligman (11) reported a lack of anesthesia in 
experiments with the hydrochloride salts of lidocaine and 
procaine dissolved in 10 - 90% DMSO. This lack of efficacy 
was explained on the basis of low concentrations of the 
drugs used and the use of the ionized salt form of the 
rugs. In many o er in vivo and in v~ro experiments, D~~u 
has been shown to increase the penetration of water and a 
variety of drugs (12,13). This increased diffusivity of the 
stratum corneum may be due to the hygroscopic nature of the 
solvent (increasing the hydration of the tissue) or 
ultrastructural modification of the stratum corneum due to 
extraction of soluble components. DMSO does not act as a 
'carrier' nor is the increased permeability due simply to a 
more favorable partition coefficient for the particular 
solute. It has been reported that the effects of DMSO are 
to a substantial degree reversible in that the permeability 
of tissue is largely restored after the DMSO is removed. 
But this point is still in dispute (9,11). 
Azone (1-dodecylazacycloheptan-2-one) has recently 
received considerable interest as a penetration enhancer. 
Stoughton (14) reported that Azone enhances the in vivo 
penetration of glucocorticoids, griseofulvin and anthracene 
in humans. In a study with hairless mouse skin, Azone was 
shown to increase the total flux of ARA-A, an anti-viral 
agent, by 20 fold as compared to a formulation using neat 
7 
DMSO (15). Azone has been promoted to enhance penetration 
of active substances without producing toxicity, altering 
sensitivity or inducing other systemic or local side 
effects. The precise mechanism is unknown, but it has been 
postulated that Azone alters the lipid and protein 
structures of the stratum corneum allowing permeation of 
act 1 ve substances in to tne der m i---s.-Radi_-o-a-c-t±ve-stu-d-i-e-s-hav-e·-----
shown that Azone is bound in the epidermis and corium and 
that relatively little is released from the skin (14,16). 
It has been reported by various authors (17-19) that 
the interaction between surfactant molecules and membrane 
components (phospholipids, proteins and water) could lead 
to changes in structure and consequently in membrane 
permeability. Experiments with rabbit skin have 
demonstrated that surfactants can change the content, 
composition, and biosynthesis rate of epidermal 
phospholipid. Since phospholipids are a major component of 
biological membranes, these changes probably indicate 
changes in epidermal membrane structure. It is believed 
that membrane lipids constitute a barrier to water 
diffusion and that the proportions of individual membrane 
lipids or their total amount can influence water and ion 
transport through these membrane. The effect of surfactants 
on the percutaneous absorption of naproxen and benzocaine 
across animal and human skin have been reported (20,21). 
These results show that, in general, nonionic surfactants 
8 
retard the percutaneous penetration of drugs. This decrease 
in penetration could be due to micelle formation thus 
affecting the concentration of 'free' drug in the solution. 
Urea has attracted interest because of its ability to 
moisturize the skin and also its capacity to act as mild 
keratolytic (22). Urea has been shown to increase the 
percutaneous pene ra ion of certarn--toyrca~-ant~ 
inflammatory steroids. Besides the hydrating action on the 
stratum corneum, urea has also been used as a solubilizer 
for various drugs (23). The effect of urea on solubility is 
due to its effect on water structure and hydrophobic 
bonding -- thus 'breaking up' water clusters surrounding 
nonpolar molecules and increasing the entropy of the system 
( 2 3) • 
It has been shown by various authors that penetration 
of drug molecules can be enhanced by increasing the 
hydration of the skin (24,25). Both occlusion and the use 
of humectants have been used in attempting to accomplish 
this goal. Compounds having humectant properties are, for 
example, propylene glycol and di-isopropyl sebacate. 
Propylene glycol has shown promising results as a vehicle 
for topical delivery when used as a co-solvent with water to 
produce saturated solutions of the active ingredient. This 
would maximize the thermodynamic activity of the penetrant. 
Selection of an appropriate propylene glycol/water mixture 
with optimal solubility and partitioning profile could 
9 
provide a solvent system to facilitate topical penetration 
of benzocaine. 
10 
Scope of the Present Study 
Incorporation of proper penetration enhancers in 
appropriate amounts could point the way to clinically 
successful formulations of topical products with an 
immediate effect on the relief of itch and pain. In view of 
this lucrative goal, this research project was designed to 
aocu men t wne t:h:er vrv.rso,-Ar i as o i ve 2-o-o , urea, an--a-A-z-o-n-e-rn.--:,-----~ 
propylene glycol/water system could enhance the 
percutaneous penetration of benzocaine through human 
cadaver skin. 
Propylene glycol was used as a co-solvent with water 
to increase the solubility of benzocaine and also for its 
possible penetration enhancement properties. Since DMSO has 
been reported to overcome the barrier properties of the 
stratum corneum with respect to other drugs, similar 
effects were expected with respect to benzocaine. 
A mixture of 60/40 (V/V) propylene glycol/water was 
chosen as the solvent system for evaluating the effects of 
selected adjuvants. The effects on both benzocaine 
solubility and percutaneous penetration were investigated. 
11 
EXPERIMENTAL 
All chemicals were used as received from the 
manufacturers and their respective lot numbers were logged. 
The solubility of the drug in a series of propylene 
glycol/water mixtures was determined. The partition 
coefficient of benzocaine in the two phase isopropyl 
myristate 
Guided by the results of solubility and partition 
coefficient determinations, an optimum composition of a 
propylene glycol/water system was chosen for the in vitro 
skin penetration studies. The effect of selected adjuvants 
on skin penetration of benzocaine was examined using this 
vehicle. 
Sol ubi li ty Studies. 
The solubility of benzocaine1 was determined in a 
series of propylene glycol2-water3 mixtures (0% to 100% in 
20% increments) at 25 + 0.5°. An excess of benzocaine 
was weighed and added to 25 ml of propylene glycol/water 
mixture in 50-ml Erlenmeyer flasks containing a Teflon 
1. 'Baker' Grade, Lot. 847340, J.T. Baker Chemical Co., 
Phillipsburg NJ 
2. U.S.P. Grade, Lot. 9011402/727341, 8395054/727341 
9124283/909349, J.T. Baker Chemical Co., 
Phillipsburg NJ 
3. Double distilled water, Univ. of the Pacific, 
Stockton CA 
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coated magnetic stirring bar and stoppered with a ground 
glass stopper. The solution was then stirred magnetically4 
for a period of 48 hours. Each determination was done in 
triplicate and the experiment conducted in a constant 
temperature room. Prior to sampling, the stirring was 
stopped and the excess drug was allowed to settle. An 
aliquot of the superna was Cake~-arrcl-:E-i-1-t-e-r-ed-w-i-t-h---------
0.22u filter 5 using a syringe with a Swinnex adapter. The 
first five ml of the filtrate was discarded to avoid any 
error due to the possible saturation and adsorption to the 
filter. After appropiate dilution, the concentration was 
determined spectrophotometrically. 
Assay Methods 
Analysis of benzocaine was done on a spectophotometer 6 
with a micro flow-through attachment. This allowed for 
small sample size and rapid sampling. The absorbance was 
recorded at 252nm (26). Beer•s Law was obeyed throughout 
the concentration range studied (1.6 to 16.02 mcg/ml). A 
standard curve was prepared for each of the propylene 
glycol/water mixtures (Appendix A-F). From these curves, 
the saturation solubility of benzocaine in each of the 
systems was calculated. 
4. Vanlab DYLA-DUAL, V.W.R., San Francisco CA 
5. Swinnex-25, Millipore Filter Corp., Bedford MA 
6. Spectronic 710, Bausch and Lomb, Rochester, NY 
13 
Partition Coefficient 
Equal volumes (100 ml) of isopropyl myristate 7 and 
different propylene glycol/water systems were allowed to 
equilibrate with respect to each other by stirring for 24 
hours. After the stirring was stopped, the two phases were 
separated by means of a separatory funnel. Excess 
benzocaine was added to 25 ml of each of the propylene 
glycol/water fractions, stirred for 48 hours and filtered 
by means of millipore filter. Three ml of the saturated 
solution of benzocaine in propylene glycol/water system was 
then agitated for 4 days with 3 ml of the respective 
propylene glycol/water saturated isopropyl myristate 
solution in stoppered test tubes. The phases were separated 
by means of centrifugation and the propylene glycol/water 
phase was analyzed for loss of benzocaine to the isopropyl 
myristate. The partition coefficient value for each of the 
propylene glycol/water systems was then calculated as the 
ratio of benzocaine concentration in isopropyl myristate to 
that of propylene glycol/water. 
7. Ruger Chemical Co. Inc., Irvington NJ 
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In Vitro Penetration Studies 
It has been reported by various authors (27) that 
there is great variability in penetration characteristics 
between human skin and animal skin. In vitro penetration 
studies done on excised human skin should provide a more 
valid representation of ~ ~ topical bioavailability in 
humans than the use of an1ma models:-Ttre~re~fur~e-a~btlo~m-i~n-al:---------­
samples of human cadaver skin were used in all penetration 
studies. 
Preparation of Skin: Abdominal skin samples obtained 
from autopsy were used as received. The skin sample was 
excised and placed in a plastic bag and stored in a freezer 
for periods up to but not exceeding three months. This 
method of storage has been reported not to damage the 
intergrity of the skin (28). Before the experiment the skin 
was removed from the freezer and allowed to thaw gradually 
at room temperature. When the sample was pliable, it was 
placed epidermal side down on a dissecting board. All 
connective and fatty tissues were removed by means of a 
scalpel. Most of the skin samples from a single donor were 
able to provide up to 10 - 12 cut pieces for use in the 
study. 
Skin Cell: The skin cell consists of two parts. The 
bottom part is a glass chamber with a sampling port and is 
enclosed by a water jacket which allows for circulation of 
water at desired temperature. A Teflon-coated magnetic stir 
~-
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bar was placed at the bottom of the chamber to ensure 
homogeneity in the chamber. The skin sample was placed in 
position on a 0-ring between the two ball joints of the top 
and bottom chambers, using a pinch type, ground-glass joint 
clamp. This exposed an effective diffusion area of 2.01 
cm 2• The top chamber was covered with parafilm during 
penetration studies to provide occlusion. Normal saline was 
injected into the lower chamber by means of a syringe and 
tubing 8 • Air bubbles that might be trapped on the dermal 
side of the skin were removed by tilting the skin cell and 
allowing them to escape via the sampling port. The cell was 
then mounted on top of a magnetic stirrer by means of a 
clamp. The temperature of the normal saline in the bottom 
chamber was maintained at 37+0.5° by circulating water 
from a constant temperature water bath9 with a circulator 
pump. The skin sample was allowed to equilibrate in this 
condition for 24 hours. Before any formulation was applied 
to the skin, the saline in the bottom chamber was removed 
and replaced with fresh saline. 
All experiments were carried out for at least 24 
hours. Samples were withdrawn at appropriate time intervals 
8. Norton Corp., Akron OH 
9. Haake Model-FE, V.W.R., San Francisco CA 
16 
and analyzed spectrophotometrically. All formulations were 
studied in duplicate. The data obtained from each run were 
computed and analyzed statistically by means of a 
computer10. The average amount penetrated per unit area per 
unit time was then plotted against time and the resultant 
steady state penetration rate was calculated. 
10. Osborne 1, Osborne Computer Corp., Hayward, CA 
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RESULTS AND DISCUSSION 
The factors which govern the passive diffusion of a 
solute from a vehicle into the skin are the physicochemical 
properties of the vehicle, the diffusant and the skin. The 
interaction of these three factors governs the rate or-arug 
penetration. In vitro percutaneous absorption of 
benzocaine and other drugs in human cadaver skin have shown 
that there is considerable variation in steady state 
penetration rates, mostly attributable to the variability 
in human skin due to any number of factors such as skin 
age, skin condition, skin site, ethnic differences and skin 
metabolism. Thus the only valid comparisons are within the 
same skin sample and from the same general area of the 
body. 
Propylene glycol has been reported to enhance 
percutaneous absorption of medicaments solubilized in it 
(28). Maximization of penetration rate from a vehicle 
requires the proper balance between the solubility of the 
drug in the vehicle and the skin/vehicle partition 
coefficient. From a plot of solubility of benzocaine in 
various propylene glycol/water mixtures and the partition 
coefficients (between propylene glycol/water mixtures and 
isopropyl myristate) against percent of propylene glycol, a 
mixture of propylene glycol and water possessing an optimum 
~-
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penetration rate could be projected. This approach provided 
useful but empirical support to the selection of a 60/40 
mixture of propylene glycol/water as the vehicle for 
further experimentation. 
Solubility Studies 
The benzocaine solubility was determined in a series 
of propylene glycol/water mixtures including the 60/40 
mixture of propylene glycol/water containing one of the 
three adjuvants, namely urea11 , polyoxythylene (20) 
isohexadecyl ether (PIE) 12 or 1-dodecylazacycloheptan-2-one 
(Azone) 13 • 
The solubility of benzocaine in 0%, 20%, 40%, 60%, 
80%, and 100% propylene glycol in water at 25+0.5° is shown 
in Table I. As can be seen, the solubility of benzocaine 
increased with increasing concentration of propylene 
glycol. 
The solubility of benzocaine in a 60/40 mixture of 
propylene glycol and water together with various adjuvants 
was also determined. Increasing the concentration of urea 
from 0.11g/ml to 0.44g/ml showed a marked increase in the 
solubility of benzocaine (Table II). However, as can be 
11. 'Baker analyzed' Grade, Lot. 8113703, J.T. Baker 
Chemical Co., Phillipsburg NJ 
12. ICI Americas Inc. Lot. 4526B, Wilmington DE 
13. Nelson Research, Lot. 0157-132 Irvine CA 
TABLE I 




















BENZOCAINE SOLUBILITY IN PROPYLENE 
CONTAINING UREA AT 























seen from the results given in Tables III and IV, 
polyoxyethylene (20) isohexadecyl ether and 
1-dodecylazacycloheptan-2-one were less effective 
in increasing solubility. Increasing percentages of 
1-dodecylazacycloheptan-2-one showed corresponding 
increase of 34% in benzocaine solubility was obtained. 
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However, the solubility of benzocaine was found to 
fluctuate between 17-28 mg/ml as the concentration of 
polyoxyethylene(20) isohexadecyl ether was increased from 0 
to 4 %. 
. -
TABLE III 
BENZOCAINE SOLUBILITY IN PROPYLENE GLYCOL/WATER b0/40 SYSTEM 
CONTAINING ARLASOLVE 200 AT 25 _::. 0.5°1 
ARLASOLVE 200 SOLUBILITY 















BENZOCAINE SOLUBILITY IN PROPYLENE GLYCOL/WATER[60/40 SYSTEM 
CONTAINING AZONE AT 25 + 0.5° 
A ZONE SOLUBIL~:TY 















The partition coefficient values of benzocaine in the 
two phase isopropyl myristate-propylene glycol/water system 
containing 20%, 40%, 60% and 80% propylene glycol in water are 
shown in Table v. These values were calculated as the ratio 
of benzocaine in isopropyl myristate phase to the amount of 
benzocaine remaining in propyiene--g17co~--pnQ~B~he--------------------~ 
solubility and partition coefficients of benzocaine as a 
function of percentage of propylene glycol in the solvent 
mixture are shown in Figs. 1-5. The relationship between 
solubility and the partition coefficient with the 
increasing percentage of propylene glycol in the system is 
graphically shown in Fig 1. and can be expressed by the 
following equations respectively: 
ln(solubility) = 0.041(% of PG) + 0.571 
ln(partition coefficient) = -0.025(% of PG) + 1.510 
As the percentage of propylene glycol in the vehicle increased, 
the partition coefficient was decreased, confirming 
the increasing tendency of the drug molecules to remain in 
the vehicle with increasing fraction of propylene glycol in 
the vehicle. This behavior negated the benefit resulting 
from the increased solubility of the drug in the donor 
phase. The choice of using isopropyl myristate as a 
partitioning phase was based on the assumption that it 
might mimic skin lipids and the stratum corneum (30). It is 
possible that by using another phase system e.g. water/oil, 
5-
TABLE V 
PARTITION COEFFICIENT OF BENZOCAINE IN ISOPROPYL MYR~STATE/PROPYLENE 

























O··\ '-o..~.----2...~-0 __ ........._40--6._0 __ 8...~-0 _ ___.~1 0__,~0 l 
% Propylene Glycol 
Semi-log plot of solubility (•) and partition 
coefficient (A) profile of benzocaine versus 




1: g Q.) 
:g3 g: - ~ Q; 
0 so_ u 
3 
-~ .a 3' :;: 
~2. -
0 20 40 60 80 100 
% Propylene Glycol 
Fig: 2. Plot of solubility (e) and partition coefficient 







0 2.0 40 60 80 
% Propylene Glycol 
100 
Fig. 3. Plot of fraction of maximum solubility (e) and 
partition (•) coefficient profile of benzocaine 
versus percent propylene glycol 
• 
0 20 40 60 80 100 








Fig. 4. Semi-log plot of fraction of maximum solubility 
(•) and partition coefficient (e) profile of 
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that different values might be obtained. Moreover, 
determination of the one vehicle with the optimum partition 
and solubility characteristics based upon this approach 
creates a real dilemma as can be seen from the various 
plots (Fig 1-5). The theorectical bases of these various 
plots were gleaned from previous works (28-30). The 
majority of our plots predicted that a 60-70 percent 
propylene glycol/water system should possess optimal 
solubility and partitioning properties. Therefore, a 
mixture of 60/40 (V/V) propylene glycol/water was chosen 




Unless otherwise indicated, all penetration studies 
were initiated using the maximum possible concentration of 
benzocaine in the vehicle. The penetration data were 
analyzed by plotting Q (amount penetrated per unit area) 
against time. A regression analysis of the data was 
region of the penetration curve were calculated by a 
computer. The different slopes were then compared to the 
centro 1 by means of the t-test see if the 1 ines were 
signifigantly parallel (statistical analysis program, 
Appendix F). In order to overcome the differences of skin 
samples from different donors and to establish a yardstick 
to compare the results of various experiments, a standard 
control with propylene glycol/water 60/40 (V/V) and 17 
mg/ml of benzocaine was included in all experiments. The 
observed penetration rates of the control range from a low 
of 7.48 to a high of 16.48 mcg/cm 2/hr with an average 
of 11.93 mcg/cm 2/hr. These variations in control values 
could be explained on the basis of the variability of human 
skin previously discussed. The relative rates were obtained by 
dividing the rate for the control into the rates for the 
test vehicles. 
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In Vitro Percutaneous Penetration of Benzocaine from 
Propylene Glycol/Water Mixtures 
The first exploratory study of skin penetration of 
benzocaine was done using different mixtures of propylene 
glycol and water (80/20, 60/40, 40/60, 20/80). It has been 
reported by Turi et al. (28) that propylene glycol 
that skin resistence decreases as the percentage of 
propylene glycol is increased. From the results, as could 
be seen from Table VI and Fig. 6, there seems to be a 
general trend in agreement with this hypothesis, but as the 
concentration of benzocaine in each of the systems is 
different, a direct correlation could not be made. It 
should also be noted that the consistancy of the 
thermodynamic flux was not maintained during the 
penetration studies. However, there was no dramatic change 
in the penetration rate as the percentage of propylene ) 
glycol in the mixture was increased -- even though 1 
statistically they were different (p<O.Ol) as compared to 
the rate of penetration of the 60/40 (V/V) propylene 
glycol/water mixture. The observed rate of penetration from 
60/40 propylene glycol/water system did not correlate with 
the empirically predicted optimum penetration rate based on 
the solubility and partitioning studies (Fig. 1). 
Realistically, the true determination of partition 
coefficient as it would relate to skin penetration could 
TABLE VI 
PENETRATION OF BENZOCAINE FROM PROPYLENE GLYCOL/WATER S~STEMS THROUGH FULL 


























Number in parentheses indicate the 95% confidence limit o~ the respective slope. 
Benzocaine was near saturation in the above solutions. 
The rates from propylene glycol/Water 80/20, 40/60, 20/80; were 















0 4 Time (hrs) 
. Fig. 6. Penetration of benzocaine from propylene glycol/ 
water systems through full thickness human skin 
Q versus t plot 
Key: % Propylene glycol/water (V/V) ~80/20 
• 60/40 a 40/60 o 20/80 
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In Vitro Percutaneous Penetration of Benzocaine from 
DMSO/Water Mixtures 
DMso14 did not enhance the penetration of benzocaine 
into the stratum corneum as compared to the control of 
60/40 propylene glycol/water as shown in Table VII, Fig. 7, 
(p>0.05). This could be due in part to the increased 
solub1l1ty of benzoca1ne iilln1~o7water system ana--------------------~ 
consequent decrease in partitioning of benzocaine into the 
receptor skin. While the concentration of 17mg/ml of 
benzocaine was at saturation level for the propylene 
glycol/water system and thus had a higher thermodynamic 
flux to penetrate into the skin, such was not the case with 
respect to benzocaine in DMSO/water mixture. On the other 
hand, it has been shown by some authors (11) that in order 
for DMSO to enhance penetration of certain compounds, a 
critical percentage of DMSO (60-80%) is necessary. The 
previously discussed phenomenon of increased hydration of 
the skin by DMSO could lead to dilution of medicaments 
applied on the skin thus underscoring the importance of 
proper experimental design based upon constant 
thermodynamic flux throughout the duration of release. 
14. 'Baker analyzed' grade, Lot. 8216688, J.T. Baker 
Chemical Co., Phillipsburg NJ 
TABLE VII 
PENETRATION OF BENZOCAINE FROM DMSO/WATER SYSTEMS [THROUGH FULL 













15.58 (.!_0. 73) 
16.14 (+0.74) 








Concentration of benzocaine in all systems was 17mg/ml. 














The rates of all DMSO/Water curves did not show any signif~gant difference as 
compared to control (p<0.05). I 
















Fig. ? •. Penetration of benzocaine from DMSO/water 
systems through full thickness human skin 
Q versus t plot 
Key: % DMSO/water {V/V) ~:>. 80/20 o 60/40 
o 40/60 • 20/80 • Control 
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Effect of Urea on the Percutaneous Penetration of 
Benzocaine 
Urea was incorporated into propylene glycol/water 
60/40 mixture in the following amounts: O.llg/ml, 0.22g/ml, 
0.33g/ml, 0.44g/ml. The saturation solubility of urea in 
propylene glycol water 60/40 mixture was determined to be 
Fig. 8, urea did not enhance the penetration of benzocaine; 
in fact, it appeared to retard the penetration of 
benzocaine. This lack of enhancement could be due to the 
increased affinity of benzocaine for the vehicle containing 
urea thus reducing the partitioning of benzocaine into the 
skin. Inadequate thermodynamic flux might have contributed 
to the findings. Feldman and Gibaldi (23) have reported 
that urea effectively breaks up the clusters of hydrogen 
bonded water surrounding the nonpolar molecules in aqueous 
solution resulting in an increase in the entropy of the 
system thus providing the energy for breaking up of 
hydrophobic bonds between nonpolar molecules. The net 
result is an increased solubility of nonpolar molecules in 
the aqueous medium. 
In the second set of experiments with urea (Table IX, 
Fig. 9), there was initial saturation of benzocaine with 
respect to each of the solutions. In this case, the urea 
enhanced the initial penetration of benzocaine into the 
stratum corneum (Fig. 10), but after the initial hour, all 
TABLE VIII 
PENETRATION OF BENZOCAINE FROM PG/WATER 60/40 SYSTEtvl 
THROUGH FULL THICKNESS HUMAN SKIN: f 
CONTAINING UREA 
I 
CONC. OF UREA RATE RELATIVE CORRJ~LATION LAG TIME 
(G/ML) (MCG/CM 2/HR) RATE COEF,,ICIENT (HR) 
-~ 
0.44 11.73 (.2:_2.43) 0.878 0.~~96 -2.10 
I 
0.33 14.93 (.2:_2.61) 1.118 0.997 -1.52 
O.l~99 0.22 14.51 (.2:_0.84) 1.087 0.20 
I 
0.11 15.98 (.2:_2.45) 1.197 0.1~98 -1.25 
I 
CONTROL 13.36 (.2:_1.13) 1 0.999 -0.52 
I 
Control = propylene glycol/water 60/40 V/V. 
Concentration of benzocaine in all systems was 17 mg/ml. 
Maximum solubility of urea in propylene glycol/water 60/4r 
The rates of benzocaine penetration from all vehicles were 
different from control (p<0.01) • 
was 0.44 g/ml. 
significantly 















Fig. 8. Penetration of benzocaine from propylene 
glycol/water 60/40 system containing urea 
through full thickness human skin: I -
Q versus t plot 
Key: Cone. of urea (g/ml) • 0.44 o 0.33 
• 0.22 ~ 0.11 • Control 
PENETRATION OF 








BENZOCAINE FROM PROPYLENE GLYCOL/WATER 60/~0 SYSTEM 
UREA THROUGH FULL THICKNESS HUMAN SKIN: I I 
RATE RELATIVE CORREL~TION 
(MCG/CM2 /HR) RATE COEFFIFIENT 
14.72 (_!.0. 71) 0.958 0.9r 
12.88 (_!. 2 • 3 7) 0.838 0.9 6 
I 
16.68 (_!.0.79) 1.085 I 0. 9914 
14.09 (_!.0.44) 0.917 0.9j7 
15.37 (_!.0.90) 1 0.9r 









Concentration of benzocaine in all system were near satur~tion with respect to 
the solution. I 
Maximum solubility of urea in propylene glycol/water 60/40 was 0.44 g/ml. 
The rates of benzocaine penetration from all Vehicles werl significantly 
different from control (p<0.01) except the vehicle contai~ing 0.44gm/ml urea 
which was not signifigantly different (p>0.05). 














0 Time (hrs) 
12 
Fig. 9. Penetration of benzocaine from propylene 
glycol/water 60/40 system containing urea 
through full thickness human skin: II -
Q versus t plot 
Key: Cone. of urea (g/ml) • 0.44 o 0.33 












Fig. 10. Initial penetration of benzocaine from 
propylene glycol/water 60/40 system containing 
urea through full thickness human skin: II -
Q versus t plot 
Key: Cone. of urea (g/ml) • 0.44 o 0.33 
• 0.22 ~ 0.11 • Control 
46 
the rates were essentially the same. The observed biphasic f 
nature of the penetration curve could be due to drug loss ( J 
from the donor solution. The hydration effect of urea on 
stratum corneum could be a time-related phenomenon. Thus if 
the skin was pretreated with urea solution and the penetration 
experiment conducted, the enhancement effect of urea might 
be more pronounced. However, urea did not exer· rr~poten~~~a~~--------~ 
penetration enhancing effect even with increased 
concentration of benzocaine. 
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Effect of Polyoxyethelene ~ Isohexadecyl Ether on the 
Percutaneous Penetration of Benzocaine 
Polyoxythylene (20) isohexadecyl ether (PIE) , a 
nonionic surfactant has been marketed as a solubilizer 
(31). The critical micelle concentration (CMC) of PIE was 
found to be between 0.005-0.009% (W/V). This was in 
agreement Wl 
supplier (0.005-0.01%) (31). 
The results shown in Table X and Fig. 11 revealed that 
PIE retarded, rather than enhanced, the penetration of 
benzocaine through full thickness human skin in the 
concentration range studied. This could be due in part to 
micellar solubilization of the drug. The resulting decrease 
in partitioning of benzocaine into the skin coupled with 
decreasing thermodynamic flux could account for the 
observed effect. The penetration rate of benzocaine was 
found to decrease as PIE concentration approached the CMC 
and increased as it exceeded the CMC. Above the CMC, less 
surfactants are available for interaction with the skin, 
provided that PIE does interact with the skin. This effect 
in conjunction with the previouly discussed phenomenon of 
micelle formation, might be used to explain the change in 
penetration rate of benzocaine around the CMC. The 
penetration rate of benzocaine from the PIE formulations 
was signifigantly (p<0.01) lower than from the control. 
Dalvi and Zatz (21) while studying nonionic surfactant 
TABLE X 
PENETRATION OF BENZOCAINE FROM PROPYLENE GLYCOL/WATER 160/40 SYSTEM WITH 
ARLASOLVE 200 THROUGH FULL THICKNESS HUMAN SKIN 










15.87 (~ 0. 9 9) 























Concentration of benzocaine in all system was 17 mg/ml. 
CMC of Arlasolve 200 was within the range 0.005 - 0.009%. 
The rates of benzocaine penetration of all vehicles were ~ignifigantly 
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Fig. 11. Penetration of benzocaine from propylene 
glycol/water 60/40 system with PIE through 
full thickness human skin : Q versus t plot 
Key: Cone. of Arlasolve 200 (W/V) 
0 0 • 0 0 0 8 % . Cl. 0 • 0 0 5% 6. 0. 0 0 7% 
• 0. 009% • 0. 07% • Control 
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effects on the penetration of dissolved benzocaine through 
hairless mouse skin observed that penetration flux from 
solutions containing a fixed benzocaine concentration was 
inversely related to surfactant concentration. For 
solutions saturated with benzocaine, surfactant 
concentration did not influence the benzocaine flux. The 
penetratio-n o£-n-e~~~o~a~~--wag-plLo~urt~-ona-r-co--ch~~re~--------------­
benzocaine concentration. Benzocaine solubilized by 
micellar entrapment would not be available for skin 
penetration. The foregoing interpretation by Dalvi and Zatz 
could not be applied directly to the PIE data in view of 
widely different levels of surfactant concentrations 
employed in the two studies and the difference in 
permeability of hairless mouse skin as compared to human 
skin. Their studies also employed significantly higher 
levels of surfactant concentration (1-5% W/V). It would 
appear that surfactant effects on penetration rate at and 
around CMC are also related to free drug concentration. 
Additional studies covering a wider range of PIE 
concentrations with varying drug concentration are 
warranted in order to fully understand the nonionic 
surfactant effects of PIE on drug penetration. 
Effect of Azone on the Percutaneous Penetration of 
Benzocaine 
51 
Azone (1-dodecylazacycloheptan-2-one) has been 
reported to enhance the percutaneous absorption of a 
variety of drugs (14-16). Azone was found to be immiscible 
with water or other polar solvents or their mixtures. In 
order to fac1l1tate 1ts incorporation into our system of 
propylene glycol/water 60/40, an emulsion and a gel were 
formulated. Since PIE was used previously and its 
percutaneous penetration characteristics were known, a 
formulation using it as a surfactant/emulsifier was 
prepared. The gel system was prepared with Klucel LF 
(hydroxypropyl cellulose) 15 , as it provided the desired 
viscosity at the concentration chosen. The four 
concentrations of Azone studied were 0.1%, 1%, 5%, and 
10% (V/V). 
1. Azone in an emulsion vehicle with PIE 
As could be seen from Table XI and Fig. 12, Azone 
appreciably enhanced the penetration of benzocaine through 
full thickness human skin. The rate of penetration in the 
steady state region was greatest with 5% Azone (5% > 1% > 
10% > 0.1% > control). However in the initial two-hour 
period (Fig. 13), the rate was greatest with 1% Azone (1% > 
5% = 0.1% > 10% > control). It is interesting to note that 
15. Grade MF, Lot. 2981, Hercules Inc., Wilmington DE 
TABLE XI 
EFFECT OF EMULSIFIED AZONE ON PERCUTANEOUS PENETRAT]ON OF BENZOCAINE 
FROM PROPYLENE GLYCOL/WATER 60/40 SYS1EM 
CONC OF AZONE 






RATE . --;~~ATI;E CORRElATION 
(MCG/CM2 /HR) RATE COEFFiCIENT 
I 
13.60 (.:!:_1.84) 1.296 
21.63 (.:!:_2.21) 2.062 
16. 71 (.:!:_1. 2 5) 1.593 
12.80 (.:!:_0.50) 1.220 







Control = propylene glycol/water 60/40 (V/V). 








0.5% (W/V) Arlasolve 200 was used in all systems to emulsify azone. 
The rates of all the Azone curves were signifigantly diffirent from the 
control curve (p<0.01). 
The numbers in parentheses indicate 95% confidence limits! of the respective 



















4 Time (hrs) 8 12 
Effect of emulsified Azone on percutaneous 
penetration of benzocaine from propylene 
glycol/water 60/40 system : Q versus t plot 
Key: Cone. of Azone (V/V) o 10% a 5% 









0.5 i Time ( hrs-) 2 
Fig. 13. Initial effect of emulsified Azone on 
percutaneous penetration of benzocaine 
from propylene glycol/water 60/40 system 
Q versus t plot 
Key: Cone. of Azone (V/V) o 10% o 5% 
• 1% • 0.1% • Control 
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Azone also overcame the mildly inhibiting effect of PIE on 
the penetration rate of benzocaine. 
2. Azone in a gel system with 4%W/V Klucel LF 
Azone was found to enhance the percutaneous 
penetration of benzocaine. The rate of enhancement in the 
steady state region was greatest with 5% Azone (5% > 1% > 
0 .1% > 1 0% > con tro 1) • Ag a l.n, s i m r1 ar re s-u-1--c-s-we-re-ob-t-a-i-nea~----~ 
in the initial two-hour period as obtained from the 
emulsion system (Table XII, Fig 14), i.e. Azone was the 
most effective enhancer at 1% concentration during the 
early stages (Fig. 15) of drug penetration (1% > 0.1% > 5% 
> 10% > control). 
3. Gel system with excess of benzocaine. 
In view of the promising potential of Azone as a 
penetration enhancer for benzocaine as determined from the 
previous two sets of experiments, a formulation of 
propylene glycol/water and azone with excess benzocaine was 
prepared. The excess benzocaine in the system provided 
maximal thermodynamic flux throughout the penetration 
period. The resultant penetration curve was biphasic with 
two distinct steady state regions (Table XIII, Fig. 16-17). 
This could be due to some artifact of the skin sample used 
or to the enhancement mechanism of Azone at work. The 
concentration of Azone that seems to provide the maximal 
penetration rate was 5%. 
TABLE XII 
EFFECT OF GELLED AZONE ON PERCUTANEOUS PENETRATIO~ OF BENZOCAINE 
FROM PROPYLENE GLYCOL/WATER 60/40 SYSTEM 




























Control = propylene glycol/water 60/40 {V/V) with 4% Kluc~l LF. 








The rates for all azone containing system were signifiganltly different from 
the control {p<0.01). 
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12 
Time (hrs) 
Fig. 14. Effect of gelled Azone on percutaneous 
penetration of benzocaine from propylene 
glycol/water 60/40 system : Q versus t plot 
Key: Cone. of Azone (V/V) o 10% o 5% 









0.5 I Time (hrs) 2 
Fig. 15. Initial effect of gelled Azone on 
percutaneous penetration of benzocaine 
from propylene glycol/water 60/40 system 
Q versus t plot 
Key: Cone. of Azone (V/V) o 10% o 5% 
• 1% • 0.1% • Control 
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TABLE XIII 
EFFECT OF GELLED AZONE ON PERCUTANEOUS PENETRATION OFIBENZOCAINE FROM 
PROPYLENE GLYCOL/WATER 60/40 SYSTEM WITH EXCESS BENZOCAINE 
CONC. OF AZONE 







(MCG/CM 2 /HR) 
I II 
27.63 (~7.06) 14.24 (~1.15) 
19.29 (~0.37) 
15.50 (~1. 73) 19.25 (~9. 74) 
9.11 (+0.53) 17.11 (~3.06) 




I 0.969 0.987 
0.999 
I 0.979 0.850 
0.995 0.969 
0.996 0.999 
Control = propylene glycol/water 60/40 (V/V) with 4% Kluc,l LF. 
Concentration of Benzocaine in all formulations was 50 mgAml. 















4 Time (hrs) 
8 12 
Effect of gelled Azone on percutaneous 
penetration of benzocaine from propylene 
glycol/water 60/40 system with excess 
benzocaine : Q versus t plot 
Key: Cone. of Azone (V/V) o 10% o 5% 
• 1% • 0.1% • Control 
61 
0.5 I Time (hrs) 
2 
Fig. 17. Initial ~ffect of gelled Azone on 
percutaneous penetration of benzocaine 
from propylene glycol/water 60/40 system 
with excess benzocaine : Q versus t plot 
Key: Cone. of Azone (V/V) o 10% o 5% 
• 1% • 0.1% • Control 
4. Azone in a gel system with excess benzocaine with 
various percentage of propylene glycol. 
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These sets of experiments were conducted since 
propylene glycol has also been reported to possess some 
concentration dependent percutaneous enhancement effects of 
its own (28). Since 5% Azone was the concentration that 
exerted this maximal penetration enhancement effece~,~a~----------------~ 
series of gelled formulations with increasing percentages 
of propylene glycol were prepared with 5% Azone, and 
percutaneous penetration of benzocaine investigated to find 
the optimal propylene glycol concentration. The 
concentration of benzocaine employed was in excess so as to 
provide for maximum thermodynamic force. The data presented 
in Table XIV and Fig. 18 reveal that rate of penetration of 
benzocaine is favored by increasing the concentration of 
propylene glycol. 
From these experiments, it can be concluded that Azone 
exhibits a concentration-dependent enhancement of 
percutaneous penetration of benzocaine. At 10% Azone in the 
formulation when benzocaine level was not at saturation, 
Azone was able to overcome this thermodynamic deficit and 
still enhance the penetration. The biphasic nature of the 
penetration curves may be suggestive of but not conclusive 
of a change in mechanism of penetration of benzocaine in 
the presence of Azone. In each of the experiments with 
TABLE XIV 
PENETRATION OF BENZOCAINE FROM GELLED PROPYLENE GLYC~L/WATER SYSTEMS 












































All the rates were signifigantly different from the propy~ene glycol/water 
0/100 control with no Azone. 














0 Time (hrs) 
12. 
Fig. 18. Penetration of benzocaine from gelled 
propylene .glycol/water systems with 
4% Klucel LF and 5% Azone through full 
thickness human skin : Q versus t plot 
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Key: % Propylena glycol/water- (V/V) o 80/20 
• 60/40 c. 40/60 Cl 20/80 • 0/100 
• Control 
65 
Azone, there was definite enhancement in the initial two 
hour period before steady state was reached. The pattern of 
high initial rates followed by slightly lower steady-state 
rates later suggests that Azone produces significant 
structural changes in the stratum corneum, lowering its 
resistance to drug penetration. However, these changes are 
possibly reversible due to dilution dur1ng sub~s-e-q-a-e-nt~---------~ 
equilibrium. If Azone is bound to the epidermis, it may 
create channels in between the flattened cells of the 
stratum corneum and allow for the passage of solubilized 
drugs. Through gross examination of the stratum corneum at 
the end of each set of runs, the stratum corneum was found 
to be intact with no visible changes. While our findings 
corraborate the results of other workers (14,15) as to the 
enhancement effect of Azone, they have failed to provide 
any additional insights into the mechanism of action of 
Azone. Further research mainly directed towards this goal 
is strongly recommended. 
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CONCLUSIONS 
The in vivo lack of efficacy of benzocaine during 
clinical trials of many OTC products has been reported by 
various authors (3,7,33). This is in part due to the fact 
that benzocaine does not effectively penetrate the stratum 
corneum. In the present stu y, tlie efrect:s of-a-n-uln~be-r-o-f-------' 
dosage form-related parameters were investigated with a view 
to enhance penetration of benzocaine topically in order to 
achieve rapid relief from itch and pain. 
1. Benzocaine solubility and partitioning 
characteristics in propylene glycol/water solvent 
systems were studied to enable identification of 
optimum levels. The in vitro findings with human 
cadaver skin did not support the empirical prediction 
of the partitioning study. This lack of predictability 
demonstrates the limitations of a simple two-phase 
system. However, if partition studies were performed 
using isolated stratum corneum, better predictive 
capability might be expected. 
2. The in vitro penetration studies strongly suggested 
that thermodynamic flux should be maintained at a 
constant during the penetration period to achieve 
optimal results and to allow one to draw meaningful 
conclusions regarding penetration enhancement effects. 
3. Of the various adjuvants investigated, Azone was 
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found to be the most effective penetration enhancer 
fo~ topical benzocaine. It appears to have its maximal 
effect on steady-state rates at a 5% V/V concentration 
and on initial rates of penetration at even lower 
Azone levels (1% V/V). 
4. Under the conditions of the experiment, DMSO did 
not enhance top1cal penetra~ion ~f--~e~u~a±ne~~--------------~ 
definitive conclusion must await further studies under 
conditions of constant thermodynamic flux together 
with higher percentages of DMSO. 
5. Interestingly, urea was found to enhance benzocaine 
penetration initially during the first hour only. The 
lack of any significant steady-state rate enhancement 
by urea even at saturated levels of benzocaine could 
be explained on the basis of a shift of thermodynamic 
flux as the experiment progressed. 
6. The results with polyoxyethylene (20) isohexadecyl 
ether are inconclusive since study was conducted over 
a narrow range of surfactant concentration. A proper 
understanding of its observed effects requires a more 
rigorous investigation of its effects on solubility 
and partitioning of benzocaine. 
7. Propylene glycol did exhibit some penetration 
enhancement effect. This effect was additive in 
the experiments with azone. 
68 
In vitro penetration studies have intrinsic 
limitations and the results of this investigation presently 
serve only as guidelines for further in vitro studies. The 
variability of the skin samples and even the variability 
within one skin sample and the chosen experimental design 
preclude drawing definitive conclusions at this time. 
Nevertheless it is generally agreed-Ehat--i~~Lv,----------------------~ 
experiment on human cadaver skin are far more reliable 
indicators of clinical action than in vitro models 
utilizing animal skins. 
A propylene glycol/water mixture has been shown to be 
a suitable vehicle for topical application of benzocaine. 
Results indicated that favorable solubility, partitioning 
and skin penetration could be obtained from such a system. 
The classical approach of adjusting the physico-chemical 
properties of the solvent system to that of the drug and 
the skin in order to enhance percutaneous absorption has 
been validated by this study. 
Significantly high initial rates of penetration of 
benzocaine with Azone strongly warrant further in vitro and 
in vivo examination • If the observed findings are 
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APPE:mrx B: Beer's law plot of benzocaine in 
propylene glycol/water 80/20 (V/V); 
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APPE~DIX D: Beer's law plot of benzocaine in 
propylene glycol/water 40/60 (V/V); 
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APPEi:miX E: Beer's law plot of benzocaine in 
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Modified computer analysis Pl""ogram from 11 l'1anLlal • of F'hannac:ol og i cal 
Cal CLll ati ons t.-Ji th CompLlter F'rogr ams 11 
by R. J. Tallarida and R. B. Murray <3S) 
20 REM -------MAIN ROUTINE--------
30 CLEAR 500 
40 DEFINT I~J~L~N 
50 DIM DA<40,20>, SRSC34)~ XC40)~ VC40), TBC101> 
60 ON ERROR GOTO 50000 
70 SC$= II ( ( F'HAF:MACOLOG I c CACULAT I ON PROGF:AM) ) II +STF: H.IG$ ( 63, II- II ) 
{------H0~;'-.c:~._I,I-.~.:f"~U.~,~$-t'.Z~~l--:-R,G:~l~NT-SC$~; '' I !'UJ"_IALl_Z I NG PROGRAM '' 
·~~~==~~------------~ 
90 LS=12:REM LINES/SCREEN 
100 ID=O:REM DATA FLAG 
110 F:ESTOF:E 
120 IL=I:READ I~SRS<I>:IF I<>O THEN 120 
130 SR$ ( I L + 1 ) =II EI\ID II : F:EI'1 LAST SF:S 
140 I=l:LC=O 
150 PRINT CHRSC26>:PRINT SC$ 
160 IF SF:$ (I) ="END" THEN I=1: LC=O: GOTO 200 
170 IF SF:$ (I)<> II II THEN F'F: I NT I; II- II; SF:$ (I) : LC=LC+ 1 
180 I=I+l 
190 IF CLC/LS=INTCLC/LS)~ AND LC<>O THEN 200 ELSE 160 
200 JF'=2:U=255:PRINT 
210 L$=" 11 : PN$= 11 ": PX$=" INDEPENDENT ',iAF:IABLE 11 : 
PY$= II DEF'ENDEI'.IT 1'/AF: I ABLE II 
220 PRINT:PRINT ''ENTER PROCEDURE # OR <RETURN> FOR NEXT PAGE 
230 U=O: INPUT U:REM ENTER SR# 
240 IF U>O AND U<34 THEN 260 
250 GOTO 150 
260 PRINT CHRSC26>:TT=C54-LEN<SR$CU)))/2 
210 PF:INT TAB <TT>; II< # 11 ; u; ~~- II; sRs w>;" >II: PRINT 
280 ON U GQSUB 1000~2000,3000,4000~5000~6000,7000,8000~9000, 
10000,11000~12000,13000,14000,15000,16000,17000,18000, 
19000,20000 . 
290 IF U<20 GOTO 310 





320 GOTO 200 
330 REM CCOMMON SUBROUTINES> 
500 F'F: I NT: I NF'UT II F'F:ESS ( ENTEF:) TO CONTI 1\!UE II ; E$: F:ETUF:N 
510 REM <CONVERT TO LOGC10)) 
520 FOR I=i TO N(J):DA<I~J)=LOG<DA<I~J))/LOG<10):NEXTI:ID=O: 
F:ETUF:N 
530 REM <PRINT CALC VALUES ? > 
540 F'F::INT:AS= 11 ":!NPUT"PF:INT CALCULATED VALUES (Y/N) "; 
AS:AS=LEFTSCA$,1) 
550 F'RINT:RETURN 
560 REM <CALC NEW VALUES ? > 
570 F'F:INT: PF:INT"ENTEF: NUMBEF: TO CALCULATE NE~J '·JALUES OR 
(099) TO CONTINUE." 
580 F:ETURN 
590 INPUT X:RETURN 
600 REM CPRINT X Y MESSAGE> 
610 IF PXS<>XL$ OR PYS<>YL$ THEN PRINT: 
F'F:INT 11 NOTE: X= ";PX':!i;:PF:INT TABC36);".,( = "~pv·s:F'RINT 
620 XL$=PXS:YL$=PYS:RETURN 
700 REM <INPUT DATA> 
710 L=O 
·720 ID=O 
730 )(L$=" 11 :YL$= 11 " 
740 J=O:N<l>=O:I=O 
750 GOSUB 610 
780 IF L< >O THEN 800 ELSE PRINT"ENTEF: NUMBEF: OF"; 
785 IF L$< >1111 THEN PF:INT L$;: ELSE 
IF JP=1 THEN PF:INT"GROUPS OF DATA ";:ELSE 
IF JF'=2 THEI'.I F'F:INT"LINES OF: CURVES II; 
790 INPUT L:L=L*JP 
800 FOR J = 1 TO L STEP JF' 
805 PF: I NT II ENTEF: NUI'1BEF: OF II 
810 IF F'N$< >II II THEN F'F: :r I'.IT F'N$; :. ELSE 
IF JP=1 THEN F·F:INT 11 0BSERVATION OF GF:OUP #";J;:ELSE 
IF JP=2 THEN F'F:INT 11 0BSEF:Vf'=.iTION OF LINE OF: CUF:VE #"; (j"+l) /2; 
840 INPUT N:IF N<=O THEN 805 
850 IF 1\1 > 100 THEN PF: I I\IT II N 1'1UST BE LESS THAN 100. II : GOTO 805 
860 NCJ>=N:IF JP=2 THEN N(J+i)=N 
870 FOR I = 1 TO N<J> 
880 IF JP=2 THEN PRINT 11 ENTEF: X~ Y PAIF: ~*";I; 
:INPUT DA<I~J)~DA<I,J+1>:GOTO 910 
890 PF: I NT II ENTEF: OBSEF:VAT I ON #II ; I ; 
900 INPUT DACI~J) 
'1'10 NEXT I, J 
920 IF L=O THEN RETURN:REM 
930 FOF: J=1 TO L 
940 F'F:II\tT: F'F:INT"GF:OUF' #"; J; II: II; 
DATA ? 
950 FOR I=1 TO N<J>:F'RINT DA<I~J>;:NEXT I 
960 NEXT J 
970 ID=l:REM SET DATA FLAG 
980 PF: I 1\tT: PF: I NT 
990 F:ETUF:N 
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2000 DATA 2~ "MEAN~ STANDAF:D DEVIATION ~/, CONFIDENCE LIMITS" 
l------'+2t)::~{~>-8-8BbJE~l-(-}t~-------------------------~ 
2050 C30SUB 2600 
2060 F:ETURN 
:2100 JF'=1:F'X$= 1111 :F'Y$=" 11 :GOSUB 710 
2200 FOR J=1 TO L 
2210 GOSUB 2660 
222(> t~.tE:~T 
2230 F:ETUF:N 
2600 N=N<1>-1:GOSUB 2960 
2605 GOSUB 2790 
2610 FOR J=1 TO L 
2620. GO SUB 281 0 
2630 NEXT 
2640 F:ETUF:N 
2650 Jl=J:GOSUB 2660:J=J+1:GOSUB 2660:J=J1:RETURN 
2660 N=NCJ):X=O:SX=O:ME=O:S2=0:DE=O:DS=O:SE=O:VA=O 




2710 FOR I=l TO N 
2720 X=DACI,J>:DS=DS+(X-ME)*(X-ME> 
:2730 NEXT 
27 40 ~/A= OS/ ( !'.1- :L ) 
2750 DE=SQF: (VA) 
2760 SE=DE/SQR<N> 
:"2:770 SX ( J) =S X: 82 ( J) =S2: DE ( J) =DE: DS < J) =DS: VA ( J) =VA: r1E ( J) = 
ME:SE<J>=SE 
2780 F:ETUF:N 
2790 PF: INT CHF:$ <27) +"1 11 ; II # N SUI"! 
STD DEV STD EF:F: 11 ; CHF:$ < 27) + 11 m 11 
2800 F:ETUF:N 
!"lEAN T '-/ALUE +/-
2810 N=NCJ>:DE=DECJ) 
2860 N=N-1:GOSUB 2960 
2870 PRINT J;TAB<3>NCJ); 
2880 CL=T~J*SE < J l 
2890 PRINT TAB<5>;SX<J>;TAB<15l;ME<J>;TABC24>;TV; 
2900 PRINT TABC33);CL; 
2910 PRINT TAB<42>;DE<Jl;TAB<51J;SE(J) 
2920 F:ETUF:N 
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2950 REM FI$ MAY BE CHANGED TO A T TABLE FILE FOR P=99 
2960 IF N>30 THEN TV=i. 96 ELSE FI':tl="TTABLE/P95 11 : 
2999 F:ETUF:N 
3000 DATi~ 3~ 11 LH.tEAF: F:EGF:ESSIOI'.I I II 
3030 GOSUB 710:REM INPUT 
3040 GOSUB 3200:REM PROCESS 
3050 GOSUB 3800:REM OUTPUT 
:3060 F:ETUF:N 
3200 GOSUB 2·200 




3240 FOR I=l TO N<Jl 
3250 X=Df=1 (I~ J) 
:3260 Y=DA C I, J+l) 
3270 XY=XY+CX*Yl 
3280 NEXT I 
3290 M=<<SX*SY/Nl-XYl/((SXA2/Nl-X2) 
3300 !VI ( J ) =tv! 
:3310 B=YM- <M*Xl'1) 
332() B (J) =B 
333C> x·\r < J) =X\' 
335() F~ETUF!I'~ 
3800 FOR J=l TO L STEP 2:GOSUB 3830:NEXT J 
3810 GOSUB 3860 
:3820 F:ETURN 
39:.::.o aosue 610: PF:INT 11 F:EGF:ESSION LINE #" ~: <J+l > /2; ": II; 
3840 PF: I NT II y = II ; M ( J) ; II* X + II ; B ( J) 
:3850 F:ETUF:N 
· .. 
3860 GO SUB 540: IF A$< >II y II THE!'•.! F:ETURN 
3870 FOR J=l TO L STEP 2:GOSUB 3880:NEXT J:RETURN 
3880 PFUNT 11 LINE #"; <J+i) /2~ "OBSEF:VED X", "OBSEF:VED Y", 
"C,~LCULATED Y 11 
3890 FOR I=l TO N<J> 
3900 YC=M(J)*DA<I,J>+B(J) 
391 o PF: r NT II II, DA < r, J) :• D1::. <I :• .J + 1 > , vc 
3920 NE)(T I 
3930 t31JSUB 570 
:3940 F'R I NT II II~ : GOSUB 5'?0: IF X=999 THEN F'FU NT: GOTO 3999 
:3950 '·(C=M ( J) *X +B ( J) : PF: I NT II II, X, "II, YC 
3960 GOTO 3940 
3999 F:ETUF:N 
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4000 DATA 4, "LINEAR F:EGRESSIOI'.I I I: LINES THF:OUGH OF:IGHl" 
4030 GOSUB 710:REM INPUT 
.4040 GOSUB 3200:REM PROCESS 
4050 GOSUB 4800:REM OUTPUT 
4060 F:ETURN 
4800 FOR J=l TO L STEP 2 
4810 PRil'H"LINE #"; (J+1) /2; II: II; 
4820 SL=XY(J)/S2<J> 
4830 GOSUB 61 (l 
4840 F'F: I NT" F:EGF:ESS I ON THF:OUGH OF: I GIN : \( = " ~ SL; "·!ol- X 11 
4850 GOSUB 540:!F A$="Y" THEN GOSUB 4880 
4860 NEXT ,J 
4870 F:;:ETURN 
4880 PF: r NT" OBSEF:'-.JED x II :• "ossEF:VED Y", "CALCULATED v" 
4890 FOR I=l TO N<J> 
4910 PRINT DA<I,J>,DA<I,J+1),YC 
4920 NEXT I 
49:::;:0 GOSUB 570 
4940 GOSUB 590:IF X=999 THEN PRINT:RETURN 
4950 vc=SL*X: PRINT ::<, "", ·y·c 


























FOR J=1 TO L STEP 2:GOSUB 5220:NEXT J:RETURN 
GOSUB 3230 
XX=O:SS=O:R=O:EM=O:EB=O:EX=O 
FOF: I= 1 TO !\1 
X-DA (I, ,J) 
XX=XX+<X-XM)*(X-XM) 
Y=DA (I~ J + 1 > 













5400 FOR J=1 TO L STEP 2:GOSUB 5410:NEXT J:GOSUB 3860:RETURN 
5410 GOSUB 3830 
5420 N=N ( J) -2: X I·$=" X-INTEF:CEPT 11 
5430 PF: I NT II COF:F:ELATI ON COEFF I c I Ei'.tT = II;; F: ( J) 
5440 PF: I NT: GOSUB 5600: T=TB ( N) : PF: I NT II ( ST AI\ID. EF:ROF:) II 
5460 p 1 ':$=II ~:3LOPE II : P2=M ( J) : P3=El"l ( J) * T: P4=El"l ( J) : GOSUB 5550 
5470 P 1 $= 11 Y-INTEF:CEPT 11 : P2=8 < J) : P3=EY < J) *T: P4=EY< J) : l30SUB 5550 
5490 P1$=XIS:P2=-8(J)/MCJ):P3=EX(J)*T:P4=EXCJ>:GOSUB 5550 
~551 0 F:ETURN 
5550 REM HOLD. POINT 
5555 PF:INT F'1 $;II = II; STR$ <P2) ~II +,/- II;; STF:$ (F'3);; II (II; STF:$ <P4); II) II 
5560 F:ETUF:I'.t 
~3600 GOSUB 2960 
5610 F'F:INT"T TABLE VALUE; = II; TV; TAB (29); "DF ="; 1\1; II p ·- 95i~" ~ 
5620 F:ETUF:N· 
5700 GOSUB 5600: F'F:INT: F'RINT"T CALCULATED = II~ ,:4BS (T) ~ 
5720 PF:H-.IT TAB (29);: IF ABS (T) <TV THEN PF:INT "NOT II; 
~57 40 F'F: I NT II sIGN IF I CAI'.IT" 
~5999 F:ETUF:r-.1 
.;SOOO DATA 6~ "PAF:ALLEL LINES I: TEST FOF: PAF:ALLELISM" 
6010 F:EM 
6020 REM SUBROUTINES: 2~3~5 
6030 GOSUB 6100:REM INPUT 
6040 GOSUB 5200:REM PROCESS 
6050 GOSUB 6800:REM OUTPUT 
6060 F:ETUF:N 
.:S 1 (H) GOSUB 71 0 
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611 0 IF L < 4 THEN PF: I NT II YOU 1'1UST HAVE MOF:E THAN ONE L I i'.iE I II : 
ID=O: GOTO .S100 
6120 F:ETUF:N 
6800 GOSUB 3050 




6850 PF:INT: PF:INT"LINE # 1 \}S. LINE #"; (J-1-1) /2; II:" 
6860 N=NC1)+NCJ>-4:GOSUB 5700 
6870 NEXT J 
6999 F:ETUF:N 
40000 DATA O~"END" 
41000 REM READ TABLE DATA 
42010 IF FI$=FL$ AND TBCN><>O THEN RETURN 
42020 PFUNT:PF:INT"ENTEF: ";FI$; "TABLE '·iALUE FOF:";i'H "D .. F."; 
4:2040 NL=N: FL$=FI$: IN$= 11 ":INPUT INS: TB CN) =VAL C IN'$) 
42050 PF: I NT 
4:21 (H) RETUF:N 
50000 PF: I NT: F:EJ'1 ERROR TRAP ROUTINES 
50030 PRINT TAB (5) *******EF:ROR - "; 
~50040 IF EF:F:=l :l THEN PRINT"DIIJISIOI'.t BY ZEF:O~ CHECK DATA!": 
F:ESUME 50090 
50050 IF ERR=5 THEN F·F:H.IT" ILLEGAL FUNCTION~ CHEC~::: DATA!": 
F:ESUME 50090 
50060 IF ERF:=8 THEN PRINT"SUBF:OUTINE DOES NOT EXIST **·lf*" ~ 
F:ESUME 50090 
50065 IF EF:F:=7 THEN PRINT"OUT OF 1'1EMOR'i <F:E-DH1ENSHJN OR F:E-F:Ui\1) ": -
F:ESUME 50999 
50070 ~-=·F:INT"ON LINE #";EF:L;". TYPE #"~EF:F:;". 
50080 RESUME 50100 
50090 GO SUB :.!. :L 0 
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